Intas Pharmaceuticals’ new warning letter from ... packing or holding of drug products that is of appropriate design, adequate size, and suitably located,” the FDA said in its report.

The plant, owned by Intas Pharmaceuticals, had hardly any working systems for ensuring the purity or sterility of its products. And its employees were trying to conceal evidence of these problems ...

Drug manufacturer Intas Pharmaceuticals is no stranger to FDA ... a warning letter that points a finger at management and labels products made at the site "adulterated" because of the company's ...

AHMEDABAD, India, Nov. 3, 2022 /PRNewswire/ -- Syna Therapeutics, a joint venture of Reig Jofre and Leanbio, has signed a global rights licensing deal with Intas Pharmaceuticals Ltd ...

Objective: This study evaluated the quality of 40 generic clarithromycin products from Latin America and Asia. Materials and Methods: The generic products were examined visually, assayed by high ...

Ahmedabad: Intas Pharmaceuticals Ltd has announced a strategic ... building on our innovative range of methotrexate products, Etanercept is a key biologic treatment which will continue to support ...

Currently ranked 6th (As per IQVIA TSA AUGUST 2023 MAT) in the Indian pharmaceutical market, it is also the largest privately owned Indian generic pharmaceutical company. While Intas has ...

In 2021, the FDA and EMA launched a parallel scientific advice pilot program for complex generic/hybrid drug products. This program aims to provide a mechanism for the FDA and EMA to jointly ...